Status:
COMPLETED
Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001
Lead Sponsor:
Collaborative Medicinal Development Pty Limited
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001
Detailed Description
Provides up to six months treatment with CuATSM for subjects who have successffulyl completed study CMD-2019-001. \[This allows subjects randomized to placebo on study CMD-2019-001 to receive up to si...
Eligibility Criteria
Inclusion
- signed informed consent prior to initiation of any study-specific procedures and treatment
- documented completion of protocol-specified assessments following completion of 24 weeks treatment on study CMD-2019-002
- Investigator considers patient has been tolerating treatment on study CMD-2019-001 and may benefit from continued treatment with CuATSM
Exclusion
- not dependent on mechanical ventilation
Key Trial Info
Start Date :
March 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 15 2022
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04313166
Start Date
March 19 2020
End Date
February 15 2022
Last Update
February 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Macquarie University
Macquarie Park, New South Wales, Australia